Product Highlight - Lanzotred

• Lanzotred is indicated for¹
  - the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
  - the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).
  - the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
  - the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

• The ratio and 90% confidence interval from the log transformed data for the pharmacokinetic parameters AUC_0-72 and C_max of enzalutamide falls within 80% to 125% where Lanzotred is proven to be bioequivalent to the innovator.²
• Lanzotred is manufactured in state-of-art facility which was approved by multiple stringent regulatory bodies.²

       References: 
       1) Lanzotred prescribing information, Jul 2022. 
       2) Lanzotred data on file.

       For Healthcare Professional Only
       R1176420-MY-CO-23062023-0850